GlassScriptPhysician profile
Donna L King
NPI 1902829443
$1,225.79
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $603 · 2022: $623.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $360.11 | 2021-2022 | |
| Esperion Therapeutics, INC. | $249.84 | 2021 | |
| Merz North America, INC. | $145.82 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $123.84 | 2022 | |
| Mylan Specialty L.P. | $96.01 | 2021 | |
| Recordati_rare_diseases_inc. | $83.10 | 2021 | |
| Novo Nordisk INC | $47.12 | 2022 | |
| Abbvie INC. | $38.55 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $33.31 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $31.24 | 2021 | |
| Collegium Pharmaceutical, INC. | $16.85 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.